Physician profile
Abdullah Haddad
NPI 1144585951
$2,165.29
in general payments reported to CMS, 2019-2025
25 companies · $228 in 2025
The $228 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $42.35 · 2022: $583 · 2023: $774 · 2024: $538 · 2025: $228.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,540.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,539.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $352.11 | 2022-2024 | Camzyos, Eliquis |
| Impulse Dynamics (USA) INC. | $331.86 | 2022-2023 | Optimizer |
| Novartis Pharmaceuticals Corporation | $330.29 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $183.46 | 2024-2025 | Verquvo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $135.60 | 2022-2024 | Lifevest |
| Amgen INC. | $116.24 | 2021-2024 | Repatha |
| Janssen Pharmaceuticals, INC | $68.23 | 2022-2023 | Xarelto |
| Cvrx, INC. | $66.41 | 2023 | Barostim Neo System |
| Novo Nordisk INC | $62.56 | 2023 | Ozempic, Rybelsus |
| Vital Connect, INC | $60.31 | 2024 | Vitalpatch Rtm |
| Scpharmaceuticals INC. | $50.42 | 2023-2025 | |
| Kestra Medical Technology Services, INC. | $44.75 | 2024-2025 | Assure Wcd |
| Boston Scientific Corporation | $41.69 | 2023-2024 | Lux-Dx Insertable Cardiac Monitor |
| Astrazeneca Pharmaceuticals LP | $39.83 | 2022-2023 | Farxiga |
| Lexicon Pharmaceuticals, INC. | $38.92 | 2023 | Inpefa |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $31.68 | 2023-2024 | |
| Actelion Pharmaceuticals US, INC. | $31.02 | 2023 | Opsumit |
| Tactile Systems Technology INC | $30.81 | 2022-2023 | Entre Plus, Flexitouch Plus |
| Heartflow, INC. | $28.30 | 2023 | Ffrct |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.22 | 2021-2022 | |
| Acist Medical Systems, INC. | $21.07 | 2024 | |
| Abiomed | $20.71 | 2024 | Impella |
| Kiniksa Pharmaceuticals, LTD. | $20.43 | 2023 | Arcalyst |
| Daiichi Sankyo INC. | $15.50 | 2022 | |
| Amarin Pharma, INC. | $14.87 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdullah Haddad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.